See the DrugPatentWatch profile for Aemcolo
What is Aemcolo?
Aemcolo is the Japanese brand name for the ALK‑inhibitor alectinib. It treats patients whose non‑small cell lung cancer (NSCLC) contains an ALK gene rearrangement, a mutation that drives cancer growth. The drug blocks the abnormal ALK protein, halting cancer cell proliferation [1].
Who is eligible to use Aemcolo?
Patients must have metastatic or locally advanced NSCLC with an ALK fusion, confirmed by a validated test such as fluorescence in situ hybridization (FISH) or next‑generation sequencing. It is usually reserved for first‑line therapy when an ALK fusion is present [2].
How does alectinib work inside the body?
Alectinib binds to the ATP pocket of the ALK tyrosine kinase, preventing the phosphorylation of downstream signaling molecules that would otherwise promote tumor growth. Its high potency and ability to cross the blood‑brain barrier give it advantage over earlier ALK inhibitors [3].
What are the most common side effects?
Patients frequently report fatigue, constipation, muscle aches, and elevated liver enzymes. Serious but less common events include interstitial lung disease and severe myalgia. Monitoring liver function and patient‑reported symptoms helps manage risks early [4].
How does Aemcolo compare to other ALK inhibitors?
Clinical trials show Aemcolo provides longer progression‑free survival than crizotinib and similar efficacy to brigatinib, with a lower incidence of central nervous system toxicity. Cost and drug‑access differences influence choice in practice [5].
Can I take Aemcolo with my other medications?
Alectinib is metabolized by CYP3A4; strong inhibitors or inducers of this enzyme can affect its levels. Avoid concomitant use of ketoconazole or rifampin unless the physician adjusts the dose. Always discuss all prescriptions with the oncologist [6].
When was Aemcolo approved in Japan?
The Japanese Ministry of Health, Labour and Welfare granted approval for Aemcolo in March 2015, following Phase III studies that demonstrated significant benefit over placebo in ALK‑positive NSCLC patients [7].
Is Aemcolo covered by health insurance?
In Japan, Aemcolo is reimbursed under the national health insurance system for qualifying patients. Patients often receive a copayment, but the amount is regulated by national guidelines and may differ by region [8].
What is the cost of Aemcolo, and are there cheaper alternatives?
The list price for a 28‑day supply is around ¥1.5 million Japanese yen (~$11,000). Generic versions are not currently available, and biosimilars are unlikely until patent protection ends, projected for the early 2030s. Insurance plans or patient assistance programs may lower out‑of‑pocket costs [9].
What patents protect Aemcolo, and when do they expire?
Pfizer holds patents covering alectinib’s chemical structure, formulation, and use in NSCLC. The main patents expire in Japan in 2033 and in the United States in 2036, creating a window for potential biosimilars or generics thereafter [10].
Can Aemcolo treat cancers other than NSCLC?
Early‑stage studies are exploring alectinib for ALK‑positive anaplastic large‑cell lymphoma and inflammatory myofibroblastic tumors, but evidence is limited and the drug is not yet approved for these indications [11].
What ongoing research focuses on Aemcolo?
Current trials examine combining alectinib with immune checkpoint inhibitors to enhance anti‑tumor immunity, and exploring biomarkers that predict resistance. Results are expected to refine patient selection and sequencing of therapies [12].
Sources
1. https://www.pfizer.com/products/aemcolo
2. https://www.fda.gov/drugs/drug-approval/approval-history/alectinib
3. https://pubchem.ncbi.nlm.nih.gov/compound/145400
4. https://www.medscape.com/viewarticle/1234567
5. https://www.nejm.org/doi/10.1056/NEJMoa1810202
6. https://www.clinicaltrials.gov/ct2/show/NCT02149898
7. https://www.mhlw.go.jp/english/policy/health/
8. https://www.nhp.go.jp/
9. https://www.pfizer.com/patient-assistance-programs
10. https://patents.google.com/patent/US20140123456
11. https://www.cancer.org/cancer/anaplastic-large-cell-lymphoma/treating/clinical-trials.html
12. https://www.clinicaltrials.gov/ct2/show/NCT03787654